Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IONS
- CUSIP: 46433010
- Web: www.ionispharma.com
Capitalization:- Market Cap: $6.74621 billion
- Outstanding Shares: 123,965,000
Average Prices:- 50 Day Moving Avg: $51.90
- 200 Day Moving Avg: $46.44
- 52 Week Range: $24.58 - $57.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -465.50
- P/E Growth: -4.87
Sales & Book Value:- Annual Revenue: $420.05 million
- Price / Sales: 16.49
- Book Value: $1.63 per share
- Price / Book: 34.27
Profitability:- EBIDTA: $33.51 million
- Net Margins: -4.80%
- Return on Equity: -14.61%
- Return on Assets: -2.21%
Debt:- Debt-to-Equity Ratio: 2.59%
- Current Ratio: 5.64%
- Quick Ratio: 5.60%
Misc:- Average Volume: 1.39 million shs.
- Beta: 3.15
- Short Ratio: 7.67
Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings results on Tuesday, May, 9th. The company reported $0.03 EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.13. The company earned $110.30 million during the quarter, compared to analysts' expectations of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 14.61% and a negative net margin of 4.80%. Ionis Pharmaceuticals's revenue was up 199.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.52) EPS. View Ionis Pharmaceuticals' Earnings History.
Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?
14 equities research analysts have issued 12-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $17.00 to $65.00. On average, they expect Ionis Pharmaceuticals' share price to reach $44.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.
What are analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/12/2017)
- 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
- 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
- 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and INC Research Holdings (INCR).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Stanley T. Crooke M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
- Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
- B. Lynne Parshall Esq., Chief Operating Officer, Corporate Secretary, Director
- Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
- C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
- Richard S. Geary Ph.D., Senior Vice President - Development
- Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
- Sarah Boyce, Chief Business Officer
- Spencer R. Berthelsen M.D., Independent Director
- Breaux B. Castleman, Independent Director
Who owns Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BLB&B Advisors LLC (0.05%), Creative Planning (0.02%), Sit Investment Associates Inc. (0.02%), Aperio Group LLC (0.01%), US Bancorp DE (0.00%) and Bank of Montreal Can (0.00%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Sit Investment Associates Inc., Creative Planning and Capstone Asset Management Co.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?
How do I buy Ionis Pharmaceuticals stock?
Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $55.86.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.29) |
| Consensus Price Target: | $44.00 (21.23% downside) |
Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/12/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $59.00 -> $62.00 | Low |  |
| 7/10/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $42.00 | Medium | |
| 5/22/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Low | |
| 5/17/2017 | Leerink Swann | Reiterated Rating | Outperform | $47.00 -> $45.00 | Medium | |
| 5/17/2017 | Needham & Company LLC | Reiterated Rating | Buy | $64.00 | Low | |
| 5/10/2017 | Piper Jaffray Companies | Set Price Target | Buy | $66.00 -> $51.00 | Low | |
| 3/10/2017 | Goldman Sachs Group, Inc. (The) | Downgrade | Neutral -> Sell | $28.00 -> $25.00 | High | |
| 1/6/2017 | Jefferies Group LLC | Reiterated Rating | Sell | $17.00 | N/A | |
| 1/5/2017 | Janney Montgomery Scott | Set Price Target | Hold | $44.00 | N/A | |
| 12/27/2016 | Laidlaw | Boost Price Target | Buy | $59.00 -> $65.00 | N/A | |
| 11/10/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $35.00 | N/A | |
| 9/11/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 8/2/2016 | Barclays PLC | Boost Price Target | Equal Weight | $26.00 -> $41.00 | N/A | |
| 8/2/2016 | Morgan Stanley | Initiated Coverage | Equal -> Equal Weight | $37.00 -> $37.00 | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.10) | $0.03 | $86.03 million | $110.30 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | $0.33 | $97.47 million | $160.30 million | View | Listen | |
| 11/9/2016 | Q316 | $0.07 | $0.06 | $114.65 million | $110.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.52) | ($0.47) | $38.52 million | $38.50 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.50) | ($0.52) | $36.21 million | $36.90 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.47) | ($0.59) | $49.32 million | $51.60 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.31) | ($0.30) | $52.93 million | $49.10 million | View | N/A | |
| 8/4/2015 | Q215 | $0.29 | $0.29 | $114.93 million | $120.40 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.19) | ($0.14) | $52.74 million | $62.60 million | View | N/A | |
| 2/27/2015 | Q414 | $0.12 | $0.25 | $74.58 million | $84.90 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.20) | ($0.23) | $45.79 million | $44.10 million | View | N/A | |
| 8/4/2014 | Q214 | ($0.12) | ($0.10) | $45.60 million | $57.08 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.23) | ($0.27) | $35.12 million | $28.20 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.17) | ($0.21) | $34.20 million | $42.25 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.27) | ($0.21) | $19.82 million | $23.60 million | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.21) | ($0.09) | $26.76 million | $38.10 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.02) | ($0.02) | $45.24 million | $43.36 million | View | Listen | |
| 2/28/2013 | Q4 2012 | ($0.23) | ($0.03) | $15.78 million | $19.90 million | View | Listen | |
| 11/6/2012 | Q312 | ($0.26) | ($0.37) | $23.11 million | $11.60 million | View | N/A | |
| 8/6/2012 | | ($0.08) | ($0.01) | | | View | N/A | |
| 5/8/2012 | | ($0.28) | ($0.24) | | | View | N/A | |
| 2/29/2012 | | ($0.13) | ($0.20) | | | View | N/A | |
| 11/7/2011 | | ($0.20) | ($0.27) | | | View | N/A | |
| 8/4/2011 | | ($0.22) | ($0.18) | | | View | N/A | |
| 5/5/2011 | | ($0.19) | ($0.20) | | | View | N/A | |
| 2/28/2011 | | ($0.22) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)2017 EPS Consensus Estimate: ($0.13)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.06) | $0.16 | $0.05 |
| Q2 2017 | 2 | ($0.38) | $0.19 | ($0.10) |
| Q3 2017 | 2 | ($0.31) | $0.22 | ($0.05) |
| Q4 2017 | 2 | ($0.30) | $0.23 | ($0.04) |
(Data provided by Zacks Investment Research)
Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 88.72%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/17/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.45 | $865,425.00 | |
| 7/3/2017 | Brett P Monia | SVP | Sell | 309 | $51.35 | $15,867.15 | |
| 7/3/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.10 | $859,650.00 | |
| 6/1/2017 | Patrick R O'neil | SVP | Sell | 70 | $48.00 | $3,360.00 | |
| 5/1/2017 | Patrick R O'neil | SVP | Sell | 650 | $48.75 | $31,687.50 | |
| 4/25/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $47.81 | $788,865.00 | |
| 4/24/2017 | Patrick R O'neil | SVP | Sell | 500 | $45.00 | $22,500.00 | |
| 4/19/2017 | Stanley T Crooke | Chairman | Sell | 5,500 | $43.25 | $237,875.00 | |
| 4/13/2017 | Stanley T Crooke | Chairman | Sell | 22,000 | $40.69 | $895,180.00 | |
| 4/12/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $40.07 | $40,070.00 | |
| 3/3/2017 | C Frank Bennett | SVP | Sell | 5,000 | $55.00 | $275,000.00 | |
| 3/1/2017 | B Lynne Parshall | COO | Sell | 4,625 | $49.26 | $227,827.50 | |
| 3/1/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $49.29 | $73,935.00 | |
| 2/6/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 1/17/2017 | B Lynne Parshall | COO | Sell | 7,246 | $46.29 | $335,417.34 | |
| 1/17/2017 | Brett P Monia | SVP | Sell | 2,502 | $46.29 | $115,817.58 | |
| 1/17/2017 | Elizabeth L Hougen | CFO | Sell | 2,273 | $46.29 | $105,217.17 | |
| 1/17/2017 | Sarah Boyce | Insider | Sell | 1,361 | $46.29 | $63,000.69 | |
| 1/17/2017 | Stanley T Crooke | CEO | Sell | 15,382 | $46.29 | $712,032.78 | |
| 1/10/2017 | Stanley T Crooke | Chairman | Sell | 13,200 | $49.25 | $650,100.00 | |
| 1/4/2017 | Stanley T Crooke | Chairman | Sell | 18,700 | $48.89 | $914,243.00 | |
| 1/3/2017 | Brett P Monia | SVP | Sell | 309 | $48.60 | $15,017.40 | |
| 12/20/2016 | Brett P Monia | SVP | Sell | 130 | $52.48 | $6,822.40 | |
| 12/15/2016 | B Lynne Parshall | COO | Sell | 4,000 | $50.00 | $200,000.00 | |
| 12/5/2016 | Elizabeth L Hougen | CFO | Sell | 2,500 | $46.05 | $115,125.00 | |
| 12/5/2016 | Patrick R O'neil | SVP | Sell | 350 | $45.00 | $15,750.00 | |
| 12/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $42.23 | $527,875.00 | |
| 11/14/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 11/11/2016 | Elizabeth L Hougen | SVP | Sell | 5,000 | $39.75 | $198,750.00 | |
| 11/7/2016 | C Frank Bennett | SVP | Sell | 5,000 | $34.00 | $170,000.00 | |
| 10/5/2016 | Stanley T Crooke | Chairman | Sell | 11,000 | $36.61 | $402,710.00 | |
| 9/27/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $36.02 | $792,440.00 | |
| 9/21/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $35.50 | $781,000.00 | |
| 9/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $29.88 | $373,500.00 | |
| 5/31/2016 | Frederick T Muto | Director | Sell | 12,500 | $22.31 | $278,875.00 | |
| 4/6/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 4/6/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $46.13 | $507,430.00 | |
| 3/31/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $40.74 | $448,140.00 | |
| 3/23/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.40 | $45,400.00 | |
| 1/19/2016 | B Lynne Parshall | COO | Sell | 5,192 | $41.46 | $215,260.32 | |
| 1/19/2016 | C Frank Bennett | SVP | Sell | 2,110 | $41.46 | $87,480.60 | |
| 1/19/2016 | Elizabeth L. Hougen | CFO | Sell | 1,899 | $41.46 | $78,732.54 | |
| 1/19/2016 | Sarah Boyce | insider | Sell | 872 | $41.46 | $36,153.12 | |
| 1/19/2016 | Stanley T. Crooke | CEO | Sell | 13,401 | $41.46 | $555,605.46 | |
| 1/5/2016 | Stanley T. Crooke | CEO | Sell | 5,500 | $62.10 | $341,550.00 | |
| 1/4/2016 | B Lynne Parshall | COO | Sell | 809 | $61.05 | $49,389.45 | |
| 1/4/2016 | Brett P. Monia | SVP | Sell | 127 | $61.00 | $7,747.00 | |
| 1/4/2016 | Stanley T. Crooke | CEO | Sell | 11,000 | $61.05 | $671,550.00 | |
| 12/16/2015 | C Frank Bennett | SVP | Sell | 7,909 | $57.41 | $454,055.69 | |
| 12/1/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $61.50 | $61,500.00 | |
| 11/11/2015 | Joseph Klein III | Director | Sell | 6,875 | $64.18 | $441,237.50 | |
| 11/10/2015 | C Frank Bennett | SVP | Sell | 5,000 | $64.00 | $320,000.00 | |
| 11/6/2015 | C Frank Bennett | SVP | Sell | 5,000 | $56.00 | $280,000.00 | |
| 11/3/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $51.95 | $51,950.00 | |
| 10/23/2015 | Stanley T. Crooke | CEO | Sell | 44,000 | $43.85 | $1,929,400.00 | |
| 10/2/2015 | B Lynne Parshall | COO | Sell | 12,436 | $40.75 | $506,767.00 | |
| 7/6/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.01 | $354,488.18 | |
| 7/6/2015 | Stanley T Crooke | CEO | Sell | 5,000 | $57.01 | $285,050.00 | |
| 7/1/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.56 | $357,908.08 | |
| 7/1/2015 | Stanley T Crooke | CEO | Sell | 6,175 | $57.56 | $355,433.00 | |
| 6/8/2015 | Brett P Monia | SVP | Sell | 7,600 | $66.22 | $503,272.00 | |
| 4/7/2015 | B Lynne Parshall | COO | Sell | 5,565 | $63.07 | $350,984.55 | |
| 4/7/2015 | Stanley T Crooke | CEO | Sell | 22,377 | $63.07 | $1,411,317.39 | |
| 3/24/2015 | C Frank Bennett | SVP | Sell | 15,000 | $70.61 | $1,059,150.00 | |
| 3/19/2015 | Elizabeth L Hougen | CFO | Sell | 10,000 | $73.33 | $733,300.00 | |
| 3/19/2015 | Patrick R O'neil | SVP | Sell | 30,525 | $74.85 | $2,284,796.25 | |
| 3/2/2015 | Joseph H Wender | Director | Sell | 7,000 | $65.97 | $461,790.00 | |
| 1/27/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $72.93 | $802,230.00 | |
| 1/16/2015 | B Lynne Parshall | COO | Sell | 4,093 | $67.96 | $278,160.28 | |
| 1/16/2015 | Elizabeth L Hougen | CFO | Sell | 1,291 | $67.96 | $87,736.36 | |
| 1/16/2015 | Richard S Geary | SVP | Sell | 1,543 | $67.96 | $104,862.28 | |
| 1/16/2015 | Stanley T Crooke | CEO | Sell | 9,054 | $67.96 | $615,309.84 | |
| 1/9/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $73.57 | $809,270.00 | |
| 1/7/2015 | Stanley T Crooke | CEO | Sell | 22,000 | $67.04 | $1,474,880.00 | |
| 1/2/2015 | B Lynne Parshall | COO | Sell | 11,200 | $62.12 | $695,744.00 | |
| 1/2/2015 | Patrick R O'neil | SVP | Sell | 1,500 | $62.12 | $93,180.00 | |
| 12/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $51.21 | $76,815.00 | |
| 11/3/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 10/30/2014 | B Lynne Parshall | COO | Sell | 11,071 | $45.12 | $499,523.52 | |
| 10/23/2014 | Stanley T Crooke | CEO | Sell | 14,600 | $42.22 | $616,412.00 | |
| 10/3/2014 | Stanley T Crooke | CEO | Sell | 36,000 | $38.52 | $1,386,720.00 | |
| 10/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $38.04 | $57,060.00 | |
| 10/1/2014 | Stanley T Crooke | CEO | Sell | 20,000 | $37.91 | $758,200.00 | |
| 8/27/2014 | C Frank Bennett | SVP | Sell | 5,000 | $40.53 | $202,650.00 | |
| 8/13/2014 | Stanley T Crooke | CEO | Sell | 15,500 | $35.45 | $549,475.00 | |
| 8/12/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.00 | $52,500.00 | |
| 8/1/2014 | Stanley T Crooke | CEO | Sell | 16,000 | $30.53 | $488,480.00 | |
| 7/31/2014 | Brett P Monia | SVP | Sell | 79 | $31.50 | $2,488.50 | |
| 7/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.33 | $52,995.00 | |
| 7/1/2014 | Stanley T Crooke | CEO | Sell | 17,500 | $35.57 | $622,475.00 | |
| 6/23/2014 | C Frank Bennett | SVP | Sell | 11,200 | $36.78 | $411,936.00 | |
| 6/19/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $35.10 | $386,100.00 | |
| 6/10/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $33.46 | $368,060.00 | |
| 6/2/2014 | Frederick T Muto | Director | Sell | 10,000 | $28.59 | $285,900.00 | |
| 4/2/2014 | Stanley Crooke | CEO | Sell | 8,800 | $43.65 | $384,120.00 | |
| 1/30/2014 | B Lynne Parshall | COO | Sell | 89,510 | $49.49 | $4,429,849.90 | |
| 1/24/2014 | Joseph Klein III | Director | Sell | 10,313 | $48.66 | $501,830.58 | |
| 1/22/2014 | Joseph Wender | Director | Sell | 10,000 | $50.98 | $509,800.00 | |
| 1/22/2014 | Richard Geary | SVP | Sell | 22,200 | $50.05 | $1,111,110.00 | |
| 1/16/2014 | B Lynne Parshall | COO | Sell | 1,641 | $47.08 | $77,258.28 | |
| 1/16/2014 | Stanley Crooke | CEO | Sell | 3,527 | $47.08 | $166,051.16 | |
| 1/8/2014 | Richard Geary | SVP | Sell | 15,000 | $40.45 | $606,750.00 | |
| 1/8/2014 | Stanley Crooke | CEO | Sell | 12,500 | $40.05 | $500,625.00 | |
| 1/2/2014 | Stanley Crooke | CEO | Sell | 31,500 | $39.35 | $1,239,525.00 | |
| 12/26/2013 | B Lynne Parshall | COO | Sell | 37,811 | $40.91 | $1,546,848.01 | |
| 12/24/2013 | B Lynne Parshall | COO | Sell | 70,000 | $41.49 | $2,904,300.00 | |
| 12/20/2013 | Joseph Wender | Director | Sell | 19,731 | $39.58 | $780,952.98 | |
| 12/5/2013 | C Frank Bennett | SVP | Sell | 10,000 | $39.92 | $399,200.00 | |
| 11/26/2013 | Joseph Wender | Director | Sell | 10,000 | $36.63 | $366,300.00 | |
| 9/20/2013 | B Lynne Parshall | COO | Sell | 90,000 | $35.43 | $3,188,700.00 | |
| 9/20/2013 | Brett Monia | SVP | Sell | 68,281 | $34.21 | $2,335,893.01 | |
| 9/20/2013 | Stanley Crooke | CEO | Sell | 58,740 | $35.19 | $2,067,060.60 | |
| 9/19/2013 | C Frank Bennett | SVP | Sell | 10,000 | $35.02 | $350,200.00 | |
| 9/11/2013 | B Lynne Parshall | COO | Sell | 63,505 | $31.04 | $1,971,195.20 | |
| 9/9/2013 | C Frank Bennett | SVP | Sell | 10,000 | $30.23 | $302,300.00 | |
| 9/4/2013 | Patrick R O'neil | SVP | Sell | 2,500 | $27.09 | $67,725.00 | |
| 8/26/2013 | Brett Monia | SVP | Sell | 2,909 | $25.58 | $74,412.22 | |
| 8/9/2013 | Joseph Klein III | Director | Sell | 18,750 | $28.22 | $529,125.00 | |
| 7/23/2013 | Stanley T Crooke | COO | Sell | 11,500 | $30.00 | $345,000.00 | |
| 7/22/2013 | Stanley T Crooke | CEO | Sell | 62,200 | $30.50 | $1,897,100.00 | |
| 7/17/2013 | Stanley T Crooke | CEO | Sell | 49,300 | $33.12 | $1,632,816.00 | |
| 7/12/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $31.75 | $2,857,500.00 | |
| 7/11/2013 | Richard S Geary | SVP | Sell | 9,000 | $31.90 | $287,100.00 | |
| 7/9/2013 | Richard S Geary | SVP | Sell | 66,163 | $30.03 | $1,986,874.89 | |
| 7/9/2013 | Stanley T Crooke | CEO | Sell | 109,172 | $26.69 | $2,913,800.68 | |
| 7/3/2013 | Richard S Geary | SVP | Sell | 5,000 | $29.02 | $145,100.00 | |
| 7/1/2013 | Stanley T Crooke | CEO | Sell | 50,683 | $27.65 | $1,401,384.95 | |
| 6/26/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $26.73 | $2,405,700.00 | |
| 6/25/2013 | Richard S Geary | SVP | Sell | 47,049 | $26.20 | $1,232,683.80 | |
| 6/20/2013 | Joseph H Wender | Director | Sell | 5,447 | $20.93 | $114,005.71 | |
| 6/11/2013 | Brett P Monia | SVP | Sell | 9,375 | $23.76 | $222,750.00 | |
| 5/30/2013 | Frederick T Muto | Director | Sell | 10,000 | $21.96 | $219,600.00 | |
| 1/16/2013 | Stanley T Crooke | CEO | Sell | 1,460 | $14.00 | $20,440.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
| Source: |
|
| Date | Headline |
|---|
 | Pro-Trader Daily: Featured Company News - Ionis Receives $10 Million Payment from Biogen
www.finanznachrichten.de - July 19 at 10:20 PM |
 | Featured Company News - Ionis Receives $10 Million Payment from Biogen
www.nasdaq.com - July 19 at 10:20 PM |
 | Akcea Therapeutics Announces Closing of Initial Public Offering
finance.yahoo.com - July 19 at 10:20 PM |
 | Ionis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB)
www.streetinsider.com - July 18 at 9:50 PM |
 | Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Sells $865,425.00 in Stock
www.americanbankingnews.com - July 18 at 7:25 PM |
| Ionis Pharma (IONS) Earns $10M Milestone Payment from Biogen (BIIB) - StreetInsider.com
www.streetinsider.com - July 18 at 2:27 AM |
| Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration
finance.yahoo.com - July 18 at 2:27 AM |
| Akcea Therapeutics Announces Pricing of Initial Public Offering
finance.yahoo.com - July 14 at 4:23 AM |
| Ionis Pharmaceuticals' (NASDAQ:IONS) "Outperform" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - July 12 at 11:50 AM |
| New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen
finance.yahoo.com - July 11 at 5:59 AM |
| New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome (FCS)
finance.yahoo.com - July 11 at 5:59 AM |
 | Ionis: Bullish Boost From Phase 3 Data - Seeking Alpha
seekingalpha.com - July 10 at 7:55 PM |
| Stifel Nicolaus Reiterates Hold Rating for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
www.americanbankingnews.com - July 10 at 6:36 PM |
| TheStreet Upgrades Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to "C-"
www.americanbankingnews.com - July 7 at 2:42 PM |
 | Commit To Purchase Ionis Pharmaceuticals At $43, Earn 14.7% Annualized Using Options - TheStreet.com
www.thestreet.com - July 7 at 6:31 AM |
| Ionis Pharamaceuticals: Will Bullish Charts and Quant Upgrade Lead to Breakout?
finance.yahoo.com - July 7 at 6:31 AM |
| Biogen's SPINRAZA™ (nusinersen) Receives Notice of Compliance from Health Canada for the Treatment of 5q Spinal Muscular Atrophy (SMA)
finance.yahoo.com - July 4 at 4:45 PM |
| Stanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - July 3 at 7:29 PM |
| Brett P. Monia Sells 309 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - July 3 at 7:28 PM |
| Akcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO - Seeking Alpha
seekingalpha.com - June 28 at 4:11 AM |
| Ionis Pharmaceuticals, Inc. (IONS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 27 at 12:14 PM |
| $83.59 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter
www.americanbankingnews.com - June 25 at 10:04 AM |
| Zacks: Brokerages Anticipate Ionis Pharmaceuticals, Inc. (IONS) to Post -$0.20 EPS
www.americanbankingnews.com - June 23 at 8:33 AM |
| Ionis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease - StreetInsider.com
www.streetinsider.com - June 22 at 6:07 PM |
| ETFs with exposure to Ionis Pharmaceuticals, Inc. : June 22, 2017
finance.yahoo.com - June 22 at 6:07 PM |
| Ionis Pharma (IONS) Completes Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease
www.streetinsider.com - June 22 at 1:05 PM |
| Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
finance.yahoo.com - June 22 at 1:05 PM |
| Akcea Therapeutics Launches Proposed Initial Public Offering
finance.yahoo.com - June 20 at 6:51 PM |
| Understanding Ionis Phamaceuticals’ Revenue Stream in 1Q17
finance.yahoo.com - June 14 at 7:54 PM |
| Akcea Therapeutics’ Volanesorsen: 1Q17 Performance
finance.yahoo.com - June 13 at 10:54 AM |
| Developments for Ionis Pharmaceuticals after 1Q17
finance.yahoo.com - June 13 at 10:54 AM |
| ETFs with exposure to Ionis Pharmaceuticals, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:32 PM |
| Changes in Ionis Pharmaceuticals’ Valuation after 1Q17
finance.yahoo.com - June 9 at 8:30 PM |
| Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 9:36 AM |
 | Why Ionis Pharmaceuticals Inc. Swooned 6% in May - Motley Fool
www.fool.com - June 7 at 11:30 PM |
| Ionis Pharmaceuticals Inc (IONS) Short Interest Update
www.americanbankingnews.com - June 6 at 3:46 PM |
| Why Ionis Pharmaceuticals Inc. Swooned 6% in May
www.fool.com - June 6 at 10:25 AM |
| Ionis Pharma (IONS) Confirms SPINRAZA Approval in European Union; Earns $50M Milestone Payment
www.streetinsider.com - June 2 at 7:24 PM |
| Ionis Pharmaceuticals' (IONS) Buy Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - June 2 at 1:14 PM |
| Ionis Pharmaceuticals Inc (IONS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 2 at 9:00 AM |
 | SPINRAZA® (nusinersen) Approved in the European Union - PR Newswire (press release)
www.prnewswire.com - June 1 at 8:22 PM |
| Ionis Pharma (IONS) Confirms SPINRAZA Approval in European ... - StreetInsider.com
www.streetinsider.com - June 1 at 3:22 PM |
| Ionis Pharmaceuticals Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - June 1 at 3:22 PM |
| SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
finance.yahoo.com - June 1 at 3:22 PM |
| SPINRAZA® (nusinersen) Approved in the European Union
finance.yahoo.com - June 1 at 3:22 PM |
| Biogen, Ionis Stocks Pop After Europe Approves $125,000 Drug
finance.yahoo.com - June 1 at 3:22 PM |
| Zacks: Analysts Anticipate Ionis Pharmaceuticals Inc (IONS) Will Post Quarterly Sales of $83.59 Million
www.americanbankingnews.com - June 1 at 1:14 PM |
| Ionis Pharmaceuticals Inc (IONS) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - May 30 at 9:10 AM |
| Akcea Announces Publication in The New England Journal of ... - PR Newswire (press release)
www.prnewswire.com - May 27 at 6:17 PM |
| Ionis Pharma (IONS) Announces Publication in NEJM of Data with AKCEA-ANGPTL3-L Rx Showing Favorable ... - StreetInsider.com
www.streetinsider.com - May 27 at 4:43 AM |
Ionis Pharmaceuticals (IONS) Chart for Friday, July, 21, 2017
